Induced Native Phage Therapy for the Treatment of Lyme Disease and Relapsing Fever: A Retrospective Review of First 14 Months in One Clinic

Abstract

The overall failure rate of standard therapeutic options for late/chronic/persistent borreliosis emphasizes the need for novel therapeutic strategies. In this report, we are presenting a novel therapeutic option based on a new technology, Induced Native Phage Therapy (INPT; PhagenCorp, LLC, Sarasota, FL), and its ability to facilitate the elimination of infection more rapidly, efficiently, and with less harm to the patient than conventional treatments. Borrelia species in the environment are themselves always infected by their own type of Borrelia bacteriophages. Both the Borrelia spirochete and the Borrelia bacteriophages are transmitted into humans via the bite of a vector, such as ticks. The Borrelia bacteriophages (phages) are called native phages in that they coexist naturally within the human body, and only infect the specific bacteria host population. Native phages persist in humans only as long as there are host bacteria of the correct type to continue replicating more phages. The purposeful manipulation of native phages to kill their host bacteria is the basis of INPT. INPT is a patent-pending technology that uses a proprietary adjunctive assay called Biospectral Emission Sequencing to identify and isolate the specific complex electromagnetic signatures necessary to induce the native phages to epigenetically revert from their normal quiescent, lysogenic activity to virulent, lytic activity, thereby killing their host bacteria. The strategic subtle, low-frequency/low-energy signatures are imprinted into a proprietary oral formula, Inducen-LD, which serves as a carrier to introduce the signals therapeutically into the body. As a proof-of-concept method validation, a total of 26 patients with post-treatment (antibiotic) Lyme disease syndrome, who initially were found upon Phelix Borrelia-phage testing (R.E.D. Laboratories, Belgium) to have one or more Borrelia species, were submitted to INPT treatment. A total of 20 patients (77%) were found to be negative after two weeks of the total program of care. Six patients who remained positive after the initial therapy received an extended INPT treatment and were retested. Four were subsequently found to be negative for one or more of their previously diagnosed Borrelia strains. Thus a total of 24 out of 26 (92%) patients were successfully treated with INPT. Mild to substantial clinical improvements were reported by all participants without noticeable adverse reactions to the INPT treatments. We have demonstrated a possible mechanism in which native bacteriophages can be induced to epigenetically switch from lysogenic to lytic actions, thereby eliminating the targeted bacteria efficiently, with little to no harm to tissues or the microbiome.

Abnormal Clots and All-Cause Mortality During the Pandemic Experiment: Five Doses of COVID-19 Vaccine Are Evidently Lethal to Nearly All Medicare Participants

“…Other factors that are literally coming to light and the electro-magnetic frequnecies at distinct wavelengths that can, like the microwaves in everyone's kitchen, be tuned to particular molecular entities from water molecules to virions, bacteria, and brain cells. Certain metals and carbon-based composites(Jernigan & Joseph, 2005;Jernigan et al 2021;Yanowitz, 2022) have been implicated along with the strange abnormal clots discussed above in this paper.…”

Lyme disease and the pursuit of a clinical cure

“…However, these discoveries need further refinement to identify specific chemical compositions and activity of these compounds as well as safety and pharmacokinetic studies in several animal models before a more conclusive determination for their efficacy can be made. Other novel treatments recommended for targeting Bb include inhibiting colonization by blocking binding to glycosaminoglycan (GAG) proteins ( 189 ), delivering toxic molecules and binding essential enzymes ( 190 ) and bacteriophage therapy ( 191 ). These innovative ideas are still in early phases of development and testing.…”

Adjunctive Testing Using Biospectral Emission Sequencing: Bioregulatory Intelligence Technology in Parallel With the Goals of Artificial Intelligence in Medicine

“…The BES findings were subsequently verified by the recently developed and highly accurate laboratory test, the Phelix Borrelia-Phage test. This test is reported as having a 96% sensitivity and 100% specificity in acute, chronic, or antibiotic-resistant infections [ 14 ].…”

“…Upon retesting using the Phelix Borrelia-Phage test, only the targeted strain was tested as eliminated, while the untreated strain persisted. When this latter strain was targeted using the BES to strategically induce other polyvalent phages to eliminate the remaining strain of Borrelia , repeat Phelix Borrelia-Phage testing resulted in it being apparently eliminated [ 14 ]. No adverse effects of the treatment were reported, nor was there a typical Jarisch-Herxheimer reaction worsening of the patient's symptoms due to the speed of bacteriophage killing of the targeted infection and the absence of bacterial toxins in Borrelia spirochetes [ 15 ].…”